Published in J Biol Chem on June 20, 2016
Artemisinin protects PC12 cells against β-amyloid-induced apoptosis through activation of the ERK1/2 signaling pathway. Redox Biol (2017) 0.75
Key aromatic/hydrophobic amino acids controlling a cross-amyloid peptide interaction versus amyloid self-assembly. J Biol Chem (2017) 0.75
Endophilin2 Interacts with GluA1 to Mediate AMPA Receptor Endocytosis Induced by Oligomeric Amyloid-β. Neural Plast (2017) 0.75
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 6.00
Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature (2002) 5.32
GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature (2003) 4.97
Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med (1998) 4.17
Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy. Nature (2015) 4.03
The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology (1990) 3.79
Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci (2010) 3.61
Molecular chaperone functions in protein folding and proteostasis. Annu Rev Biochem (2013) 3.56
Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell (2013) 3.24
Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol (2000) 2.91
Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature (2002) 2.71
Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci (2010) 2.66
beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.40
Seeding specificity in amyloid growth induced by heterologous fibrils. J Biol Chem (2004) 2.35
Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J (2007) 2.25
Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci (2010) 2.12
Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging (2005) 2.11
Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci (2001) 1.95
Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol (1998) 1.93
Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem Res (2006) 1.91
Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS One (2008) 1.84
Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am J Pathol (2008) 1.65
Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim Biophys Acta (2001) 1.63
Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol Psychiatry (2004) 1.62
Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol Sci (2002) 1.62
Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nat Neurosci (2015) 1.60
Islet amyloid polypeptide-induced membrane leakage involves uptake of lipids by forming amyloid fibers. FEBS Lett (2004) 1.59
Alzheimer's beta-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. J Biol Chem (2000) 1.59
Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron (2008) 1.49
The effect of macromolecular crowding on protein aggregation and amyloid fibril formation. J Mol Recognit (2004) 1.48
Proteolytic degradation of amyloid β-protein. Cold Spring Harb Perspect Med (2012) 1.46
Extracellular α--synuclein-a novel and crucial factor in Lewy body diseases. Nat Rev Neurol (2014) 1.44
Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.41
Transthyretin (TTR) cardiac amyloidosis. Circulation (2012) 1.40
Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases. J Neurosci (2010) 1.33
Alzheimer's disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization. Proc Natl Acad Sci U S A (2010) 1.28
Evidence of a role for lactadherin in Alzheimer's disease. Am J Pathol (2007) 1.28
Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation. Neurobiol Aging (2004) 1.27
Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. Arch Neurol (2012) 1.26
High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun (1999) 1.23
Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid (2006) 1.22
Amyloid-beta42 interacts mainly with insoluble prion protein in the Alzheimer brain. J Biol Chem (2011) 1.22
The case for rejecting the amyloid cascade hypothesis. Nat Neurosci (2015) 1.21
Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. J Biol Chem (2010) 1.20
Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry (2001) 1.18
An N-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivo. J Biol Chem (2013) 1.18
Cystatin C protects neuronal cells from amyloid-beta-induced toxicity. J Alzheimers Dis (2010) 1.17
Amyloid β-sheet mimics that antagonize protein aggregation and reduce amyloid toxicity. Nat Chem (2012) 1.16
Tau in physiology and pathology. Nat Rev Neurosci (2015) 1.15
The clinical and biological relationship between Type II diabetes mellitus and Alzheimer's disease. Curr Alzheimer Res (2004) 1.14
Identification of hot regions of the Abeta-IAPP interaction interface as high-affinity binding sites in both cross- and self-association. Angew Chem Int Ed Engl (2010) 1.13
IAPP mimic blocks Abeta cytotoxic self-assembly: cross-suppression of amyloid toxicity of Abeta and IAPP suggests a molecular link between Alzheimer's disease and type II diabetes. Angew Chem Int Ed Engl (2007) 1.11
Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease. J Alzheimers Dis (2009) 1.11
Inhibition of amyloid fibrillogenesis and toxicity by a peptide chaperone. Mol Cell Biochem (2004) 1.09
Transthyretin binding to A-Beta peptide--impact on A-Beta fibrillogenesis and toxicity. FEBS Lett (2008) 1.09
Cross-seeding effects of amyloid β-protein and α-synuclein. J Neurochem (2012) 1.08
Islet amyloid: from fundamental biophysics to mechanisms of cytotoxicity. FEBS Lett (2013) 1.08
Cystatin C reduces the in vitro formation of soluble Abeta1-42 oligomers and protofibrils. Scand J Clin Lab Invest (2007) 1.07
Fibrinogen and altered hemostasis in Alzheimer's disease. J Alzheimers Dis (2012) 1.06
Familial Alzheimer's disease mutations differentially alter amyloid β-protein oligomerization. ACS Chem Neurosci (2012) 1.05
Phenylalanine assembly into toxic fibrils suggests amyloid etiology in phenylketonuria. Nat Chem Biol (2012) 1.05
AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiol Aging (2011) 1.03
Prion protein-mediated toxicity of amyloid-β oligomers requires lipid rafts and the transmembrane LRP1. J Biol Chem (2013) 1.01
Amyloid-β nanotubes are associated with prion protein-dependent synaptotoxicity. Nat Commun (2013) 1.00
Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease? Mol Neurodegener (2011) 0.99
Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide (1 40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes. Mol Pharmacol (2007) 0.99
Cathepsin B degrades amyloid-β in mice expressing wild-type human amyloid precursor protein. J Biol Chem (2012) 0.97
Soluble prion protein inhibits amyloid-β (Aβ) fibrillization and toxicity. J Biol Chem (2012) 0.96
Antibody drugs for Alzheimer's show glimmers of promise. Nature (2015) 0.95
Cystatin C in Alzheimer's disease. Front Mol Neurosci (2012) 0.94
APOA1 polymorphism influences risk for early-onset nonfamiliar AD. Ann Neurol (2005) 0.94
Prion protein is reduced in aging and in sporadic but not in familial Alzheimer's disease. J Alzheimers Dis (2010) 0.94
Transthyretin influences spatial reference memory. Neurobiol Learn Mem (2007) 0.94
Identification of beta-amyloid-binding sites on transthyretin. Protein Eng Des Sel (2012) 0.91
Cu(2+) affects amyloid-β (1-42) aggregation by increasing peptide-peptide binding forces. PLoS One (2013) 0.88
Mouse and rat cystatin C: Escherichia coli production, characterization and tissue distribution. Comp Biochem Physiol B Biochem Mol Biol (1996) 0.88
Non-chaperone proteins can inhibit aggregation and cytotoxicity of Alzheimer amyloid β peptide. J Biol Chem (2014) 0.87
Intracellular alpha-synuclein affects early maturation of primary oligodendrocyte progenitor cells. Mol Cell Neurosci (2014) 0.86
Serum amyloid P component accelerates the formation and enhances the stability of amyloid fibrils in a physiologically significant under-saturated solution of amyloid-β42. J Alzheimers Dis (2012) 0.86
Selectively N-methylated soluble IAPP mimics as potent IAPP receptor agonists and nanomolar inhibitors of cytotoxic self-assembly of both IAPP and Aβ40. Angew Chem Int Ed Engl (2013) 0.85
Overexpression of superoxide dismutase 1 protects against beta-amyloid peptide toxicity: effect of estrogen and copper chelators. Neurochem Int (2004) 0.84
Huntingtin associated protein 1 regulates trafficking of the amyloid precursor protein and modulates amyloid beta levels in neurons. J Neurochem (2012) 0.84
Protective properties of lysozyme on β-amyloid pathology: implications for Alzheimer disease. Neurobiol Dis (2015) 0.84
Complexes of amyloid-beta and cystatin C in the human central nervous system. J Alzheimers Dis (2009) 0.83
Cellular polyamines promote amyloid-beta (Aβ) peptide fibrillation and modulate the aggregation pathways. ACS Chem Neurosci (2013) 0.83
Human lysozyme inhibits the in vitro aggregation of Aβ peptides, which in vivo are associated with Alzheimer's disease. Chem Commun (Camb) (2013) 0.83
Amyloid and tau pathology of familial Alzheimer's disease APP/PS1 mouse model in a senescence phenotype background (SAMP8). Age (Dordr) (2015) 0.82
Biophysical studies of the amyloid β-peptide: interactions with metal ions and small molecules. Chembiochem (2013) 0.82
Experimental induction of type 2 diabetes in aging-accelerated mice triggered Alzheimer-like pathology and memory deficits. J Alzheimers Dis (2014) 0.81
Transthyretin stabilization by iododiflunisal promotes amyloid-β peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer's disease mouse model. J Alzheimers Dis (2014) 0.81
The hairpin conformation of the amyloid β peptide is an important structural motif along the aggregation pathway. J Biol Inorg Chem (2014) 0.81
Deficiency of the copper chaperone for superoxide dismutase increases amyloid-β production. J Alzheimers Dis (2010) 0.81
Inhibiting and reversing amyloid-β peptide (1-40) fibril formation with gramicidin S and engineered analogues. Chemistry (2013) 0.79
Endogenous polyamines reduce the toxicity of soluble aβ peptide aggregates associated with Alzheimer's disease. Biomacromolecules (2014) 0.79
The Aβ peptide forms non-amyloid fibrils in the presence of carbon nanotubes. Nanoscale (2014) 0.77
Characterization of Mn(II) ion binding to the amyloid-β peptide in Alzheimer's disease. J Trace Elem Med Biol (2016) 0.77
Cyclic peptides as inhibitors of amyloid fibrillation. Chemistry (2014) 0.77
Alzheimer peptides aggregate into transient nanoglobules that nucleate fibrils. Biochemistry (2014) 0.77
Reciprocal Molecular Interactions between the Aβ Peptide Linked to Alzheimer's Disease and Insulin Linked to Diabetes Mellitus Type II. ACS Chem Neurosci (2016) 0.75